All 54 peptides.

Small-molecule NNMT inhibitor with intriguing mouse-adipocyte data. Almost no human evidence. Tier 3/4. Marketed for fat loss far ahead of the data.

Dose

50–150 mg · once daily

Route

Oral / Subcutaneous (compounding-pharmacy off-label)

Indications

3 indexed

Marketed as a 'fat-burning peptide' but the most rigorous human trial — Metabolic Pharmaceuticals' Phase 2b in obesity — failed its primary endpoint. Hold the line: the data don't match the marketing.

Dose

0.25–1 mg · once daily

Route

Subcutaneous / Oral (sublingual / troche, low bioavailability) / Topical (cosmetic compounding)

Indications

3 indexed

Compounded injectable B-vitamin combination, typically B1+B2+B3+B5+B6+B12. Tier 1 for any actual B-vitamin deficiency; Tier 4 for the 'energy boost' marketing in replete adults.

Dose

1–2 mg · weekly to every 2–4 weeks

Route

Intramuscular / Subcutaneous / Intravenous (clinic infusions, often as part of 'Myers cocktail')

Indications

5 indexed

Standard injectable B12 — Tier 1 for B12 deficiency. The cyanocobalamin form is the cheapest and most-shelf-stable; methylcobalamin is preferred by community users for theoretical reasons that do not have strong human-outcome evidence behind them.

Dose

1 mg · weekly for 4 weeks then monthly

Route

Intramuscular / Subcutaneous / Oral (high-dose) / Sublingual / Intranasal (Nascobal)

Indications

4 indexed

Vitamin B12 in the methyl form. Solid evidence for treating documented deficiency and pernicious anemia. The wellness-clinic 'energy injection' market for non-deficient adults has no clinical-trial support.

Dose

1 mg · weekly to monthly

Route

Intramuscular / Subcutaneous / Oral (high-dose) / Sublingual / Intranasal (Nascobal, FDA-approved)

Indications

6 indexed

Extensively studied in rodents for tissue healing across tendon, gut, vascular, and CNS injury models. Human evidence is essentially absent — community framing far outpaces the data.

Dose

250–500 mcg · 1–2× daily

Route

Subcutaneous / Intramuscular / Oral (research only)

Indications

4 indexed

Russian-developed anti-asthenic. Indirect dopaminergic effect via tyrosine hydroxylase upregulation. Tier 3 in Russian clinical literature; no Western replication. WADA-banned for athletes. Not technically a peptide — included for community completeness.

Dose

50–100 mg · once daily

Route

Oral

Indications

3 indexed

Long-acting GHRH analog often paired with a GHRP. Strong PK data in humans; outcome data is limited.

Dose

30–250 mcg · see notes

Route

Subcutaneous

Indications

3 indexed

The most widely used GH-restoration protocol — GHRH amplification plus a clean GHRP pulse in one bedtime injection. The combination mimics natural GH physiology more closely than either alone.

Dose

250 mcg · 5 days/week (10 units of a 5/5 mg vial = 250 mcg of each)

Route

subcutaneous

Indications

3 indexed

Once-weekly fixed-dose combination of GLP-1 (semaglutide) + amylin (cagrilintide) — two satiety mechanisms for substantially greater weight loss than semaglutide alone.

Dose

0.25–2.4 mg · once weekly (each component titrated to 2.4 mg)

Route

subcutaneous

Indications

2 indexed

Long-acting amylin analog for once-weekly subcutaneous dosing; the other half of CagriSema.

Dose

0.3–4.5 mg · once weekly

Route

Subcutaneous

Indications

4 indexed

Multi-peptide cocktail from porcine brain, manufactured by EVER Pharma. Approved in Europe / Asia / Russia for ischemic stroke, dementia, and TBI. NOT US-approved. Tier 1/2 abroad in approved indications; Tier 3 for off-label use.

Dose

5,000–50,000 mg · once daily, courses of 10–30 days, repeated

Route

Intramuscular / Slow intravenous infusion

Indications

5 indexed

Discovered in 1977. A handful of small clinical studies in the 1980s for sleep, narcolepsy, and opioid withdrawal. The evidence is thin, old, and largely unreplicated. Tier 3.

Dose

100–500 mcg · once daily, evening

Route

Subcutaneous / Intranasal / Intravenous (historical research)

Indications

4 indexed

Animal-only peptide aimed at restoring brain connections, with replicated cognitive-recovery signals in rodent models of Alzheimer's disease. No human trials.

Dose

10–45 mg · once daily

Route

Oral (community use) / Sublingual (community use) / Intranasal (research)

Indications

4 indexed

Synthetic tetrapeptide claimed to extend telomere length and reduce all-cause mortality in older adults.

Dose

5–10 mg · once daily, courses of 10–20 days

Route

Subcutaneous / Intramuscular / Intranasal (Russian use)

Indications

4 indexed

Senolytic peptide designed to selectively kill aged cells. Mouse data only — no published human trials.

Dose

5–50 mcg · every 2–3 days for 3 doses, then cycled

Route

Intravenous (research) / Subcutaneous (community use, off-label)

Indications

2 indexed

Strong topical evidence in skin and wound healing. Injectable systemic claims are an entirely different evidence base and tier.

Dose

1–5 mg · 1× daily

Route

Topical (creams/serums) / Subcutaneous (research only)

Indications

3 indexed

GHRP with reliable acute GH release (Tier 2) and a profile between ipamorelin (cleaner) and GHRP-6 (more appetite). Approved in Japan as a diagnostic stim test for GH deficiency under the name pralmorelin.

Dose

100–300 mcg · 1–3× daily

Route

Subcutaneous / Intravenous (diagnostic use in Japan) / Intranasal (research)

Indications

4 indexed

Older GH-releasing peptide that also stimulates appetite through the ghrelin receptor — a feature for some users, a side effect for others.

Dose

100–300 mcg · 1–3× daily

Route

Subcutaneous / Intranasal (research, less common) / Intravenous (research)

Indications

4 indexed

Adds GHK-Cu's gene-expression and collagen action on top of the Wolverine repair pair, for aesthetics plus deep-tissue recovery. All three are pH-compatible; the triple combo has no RCT of its own.

Dose

1.67 mg · 7 days/week (10 units of a 50/10/10 mg vial)

Route

subcutaneous

Indications

3 indexed

Endogenous tripeptide antioxidant. The cellular antioxidant mechanism is real, and the upstream precursor (N-acetylcysteine) is the standard antidote for paracetamol overdose. Aggressively marketed by IV clinics and the skin-lightening industry — most cosmetic and 'detox' claims run well past the evidence.

Dose

200–2,000 mg · 1–3× per week (clinic IV)

Route

Intravenous / Subcutaneous (compounded) / Intranasal (research / community) / Inhaled / nebulized (research) / Oral (liposomal preparations)

Indications

5 indexed

Most potent acute GH-releaser of the classic GHRPs; cortisol and prolactin spike with sustained dosing, and tachyphylaxis builds quickly.

Dose

100–200 mcg · 1–2× daily, cycled

Route

Subcutaneous / Intravenous (research) / Intranasal (research, less common)

Indications

3 indexed

Bodybuilding community use. Tier 3 with serious safety flags: hypoglycemia from insulin-receptor cross-activity, unrestricted growth-tissue stimulation, theoretical cancer concerns. The evidence is thin and the risks are real.

Dose

20–80 mcg · once daily

Route

Subcutaneous / Intramuscular (community 'site injection')

Indications

3 indexed

Selective GH-releasing peptide with minimal cortisol or prolactin elevation in early studies. Human outcome evidence is limited.

Dose

100–300 mcg · 1–3× daily

Route

Subcutaneous / Intramuscular

Indications

4 indexed

Short tripeptide fragment of a natural hormone (alpha-MSH). Appears to carry the anti-inflammatory signaling of the parent hormone without its pigmentation effects. Growing animal and early-human work, especially for inflammatory bowel disease.

Dose

0.25–1 mg · 1–2× daily

Route

Oral (gut-targeted) / Subcutaneous / Topical (research)

Indications

4 indexed

Sits at the very top of the reproductive axis — triggers the cascade that produces sex hormones. Strong clinical-research evidence for hypogonadism and IVF use; off-label 'natural T' community use in healthy men runs ahead of the data.

Dose

1–12 mcg · pulsatile (e.g., every 90 minutes for hypothalamic amenorrhea)

Route

Intravenous (research clinical use) / Subcutaneous / Intranasal (research)

Indications

5 indexed

Glow plus KPV's targeted NF-κB anti-inflammation — built for complex injuries with a heavy inflammatory or gut component. All four are pH-compatible; the four-way combo has no RCT of its own.

Dose

0.5–1.25 mg · 7 days/week (15 units of a 10/25/10/10 mg vial)

Route

subcutaneous

Indications

3 indexed

The only human cathelicidin — broad antimicrobial plus host-defense modulation. Mechanism is well characterized; human RCT data for therapeutic use is limited.

Dose

250–500 mcg · 1–2× daily

Route

subcutaneous

Indications

4 indexed

Furthest-developed clinical-stage peptide for celiac disease. The pivotal Phase 3 trials missed their primary endpoints; community marketing for general 'leaky gut' goes far past the evidence.

Dose

0.5–2 mg · 3× daily before meals

Route

Oral (capsule, before meals)

Indications

3 indexed

Orally bioavailable small molecule that elevates GH and IGF-1. Multiple human RCTs confirm the hormone effect; clinical-outcome benefits are far less settled.

Dose

10–25 mg · once daily

Route

Oral

Indications

5 indexed

Mitochondrial-encoded peptide with strong rodent data on insulin sensitivity, endurance, and metabolic health.

Dose

5–10 mg · 2–3× per week

Route

Subcutaneous / Intramuscular (research only)

Indications

4 indexed

FDA-approved as Scenesse / afamelanotide for a rare genetic light-sensitivity disorder (erythropoietic protoporphyria). Note: this is the regulated melanocortin sibling — distinct from the more popular community 'tanning peptide' MT-2.

Dose

16 mg · every 2 months

Route

Subcutaneous implant (Scenesse, FDA-approved) / Subcutaneous injection (off-label / research)

Indications

4 indexed

The popular community 'tanning peptide' — and the high-risk one. Serious safety flags: priapism, melanoma surveillance concerns, nausea, blood pressure effects. NOT the FDA-approved MT-1 / Scenesse molecule.

Dose

0.25–1 mg · loading: every 1–2 days; maintenance: 1–2× weekly

Route

Subcutaneous / Intranasal (off-label / community)

Indications

3 indexed

Coenzyme central to redox biology, marketed as IV / SubQ / oral and via NMN/NR precursors. Most clinical claims rest on weak or contested evidence; bioavailability is a real, unresolved question.

Dose

100–1,000 mg · once daily

Route

Oral (NR, NMN, niacin) / Intravenous / Subcutaneous / Intranasal

Indications

5 indexed

Oral NAD+ precursor with growing — but contested — human data. Bioavailability is the unresolved question: oral NMN is largely converted to NR before it reaches cells.

Dose

100–1,200 mg · once daily

Route

Oral / Sublingual (limited PK data) / Subcutaneous (off-label compounding)

Indications

4 indexed

Oral NAD+ precursor with consistent evidence that it raises blood NAD+ in humans — but underwhelming evidence that the NAD+ rise translates to clinical outcomes outside specific populations.

Dose

250–1,000 mg · once daily

Route

Oral (capsule)

Indications

5 indexed

The labor-induction hormone (Pitocin), FDA-approved since 1962. Off-label nasal and subcutaneous use — for autism social cognition, 'bonding,' anxiolysis — has loud community framing but a messier and partly negative randomized-trial literature.

Dose

1–40 mcg · continuous IV titration

Route

Intravenous (FDA-approved) / Intramuscular / Intranasal (off-label) / Subcutaneous (off-label) / Buccal (research)

Indications

6 indexed

Animal-only compound designed to mimic a brain growth factor. Strong rodent data on new neuron formation and cognitive recovery in disease models; zero published human evidence.

Dose

0.1–1 mg · once daily (varies wildly)

Route

Oral (community use) / Subcutaneous (community use) / Intranasal (research)

Indications

3 indexed

FDA-approved as Vyleesi for premenopausal HSDD. Off-label use for male erectile function and on-demand libido is widespread but supported by far thinner evidence.

Dose

1.75 mg · as needed, ≤1 dose per 24 hours and ≤8 doses per month

Route

Subcutaneous / Intranasal (historical, discontinued formulation)

Indications

4 indexed

Synthetic tripeptide positioned as a cognitive and neuroprotective bioregulator; community use is intranasal.

Dose

1–2 mg · once daily during the 21-day cycle

Route

subcutaneous / intranasal

Indications

4 indexed

Approved immunosuppressant for transplant; the canonical mTOR inhibitor. Off-label longevity dosing (5–8 mg weekly) is widely community-practiced; PEARL Phase 2 (2024) is the largest healthy-adult RCT and was equivocal.

Dose

1–8 mg · once weekly (longevity off-label) or once daily (transplant)

Route

Oral (tablet or solution)

Indications

5 indexed

Investigational triple-incretin agonist (GLP-1 + GIP + glucagon) with the largest weight-loss effect sizes reported to date in Phase 2. Phase 3 still enrolling.

Dose

1–12 mg · once weekly

Route

Subcutaneous

Indications

4 indexed

Mitochondrial-targeted peptide. FDA-approved for Barth syndrome (2024); explored in other mitochondrial conditions and as a longevity compound.

Dose

40–60 mg · once daily

Route

Subcutaneous / Intravenous (clinical trials)

Indications

4 indexed

Russian-developed anxiolytic/nootropic peptide. Most clinical data is in Russian and methodologically thin by Western standards. Tier 3. Routes include intranasal — a natural pair with Juno's nasal-spray prep guide.

Dose

250–900 mcg · 1–3× daily

Route

Intranasal / Subcutaneous

Indications

4 indexed

The most-studied GLP-1 agonist in modern medicine, with Tier 1 evidence for diabetes, weight loss, and major adverse cardiovascular events.

Dose

0.25–2.4 mg · once weekly

Route

Subcutaneous / Oral (Rybelsus formulation)

Indications

4 indexed

Russian-developed nootropic and neuroprotective peptide. Registered there as a prescription product for stroke; most of the clinical evidence is Russian-language and not independently replicated outside that body of work.

Dose

0.6–9 mg · 1–3× daily

Route

Intranasal / Subcutaneous (research / community)

Indications

4 indexed

FDA-approved historically for pediatric GH deficiency. Adult anti-aging use is widespread but off-label and weakly supported.

Dose

200–500 mcg · once daily at bedtime

Route

Subcutaneous / Intravenous (diagnostic only)

Indications

4 indexed

Animal-data peptide marketed as a tissue-repair adjunct. No published human RCTs for musculoskeletal indications.

Dose

2–5 mg · twice weekly (loading) → weekly (maintenance)

Route

Subcutaneous / Intramuscular

Indications

3 indexed

FDA-approved for HIV-associated lipodystrophy. Off-label use for general fat loss is meaningfully less supported.

Dose

2 mg · once daily

Route

Subcutaneous

Indications

5 indexed

Tesamorelin's proven visceral-fat targeting plus Ipamorelin's clean GH pulse in one bedtime injection — visceral fat reduction with broader GH-axis support.

Dose

1 mg · 5 days/week (30 units of a 10/5 mg vial)

Route

subcutaneous

Indications

3 indexed

Approved in 30+ countries for chronic hepatitis B and C and as a sepsis adjunct in critically ill patients — but not in the US. Evidence quality varies sharply by indication, and the popular 'general immune support' framing has no clinical backing.

Dose

0.9–1.6 mg · twice weekly

Route

Subcutaneous / Intravenous

Indications

5 indexed

FDA-approved dual incretin agonist with the strongest weight-loss and glycemic data in this library.

Dose

2.5–15 mg · once weekly

Route

Subcutaneous

Indications

4 indexed

Tier 1 for vitamin D deficiency; injectable IM forms are mostly used in malabsorption or compliance-failure populations. Most users should take oral D3 — it works fine and is far cheaper.

Dose

25–100 mcg · once daily (oral, ongoing)

Route

Oral (capsule, drops, liquid) / Intramuscular (high-dose) / Subcutaneous (rare, compounded)

Indications

7 indexed

The most common soft-tissue repair pairing — angiogenesis plus actin-driven cell migration. Co-injectable because the two are pH-compatible; the evidence remains preclinical.

Dose

500 mcg · 7 days/week (15 units of a 10/10 mg vial = 500 mcg of each)

Route

subcutaneous

Indications

3 indexed